(function(){
			var content_array=["<p><strong>卫材简介<\/strong><\/p> \n<p>卫材在中国脑健康领域耕耘二十多年，一直秉承关心人类健康（human health care）的企业使命，始终支持&quot;脑健康行动&quot;所提出的各项主张和措施，并积极参与AD科普手册科普宣传。关注记忆健康，提倡早筛、早诊、早治，不仅是公司的责任，也是作为社会成员的责任。<\/p> \n<p><sup>[1] 中国痴呆与认知障碍指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会.2018中国痴呆与认知障碍诊治指南(一):痴呆及其分类诊断标准.中华医学杂志.2018;98(13):965-970<br \/><\/sup><sup>[2] Jia L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in <span class=\"xn-location\">China<\/span>: a cross‑sectional study. Lancet Public Health. 2020;5(12): e661‑e671<br \/><\/sup><sup>[3] Jia J, et al.Alzheimers Dement. 2018 Apr;14(4):483 491.<br \/><\/sup><sup>[4] Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci. 2018;11(2):147-152<br \/><\/sup><sup>[5] <span class=\"xn-person\">Michael C. Irizarry<\/span>, AAIC 2023 presentation&quot;Lecanemab : Amyloid Reduction and Evidence of Downstream Biomarker Modification&quot;.<br \/><\/sup><sup>[6] lecanemab-irmb injection (LEQEMBI<sup>&reg;<\/sup>), FDA label（ 202307）<br \/><\/sup><sup>[7] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease[J]. N Engl J Med,&nbsp; 2023, 388(1):9-21<br \/><\/sup><sup>[8] <span class=\"xn-person\">Keith Johnson<\/span>. CTAD 2023 presentation&quot;Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker&quot;.<\/sup><\/p> \n<p>&nbsp;<\/p> \n<div id=\"DivAssetPlaceHolder0\" class=\"PRN_ImbeddedAssetReference\">\n &nbsp;\n<\/div>"];
			$("#dvExtra").html(content_array[0]);})();